On Jan. 7, 2021, PerkinElmer and Oxford Immunotec announce an agreement under which PerkinElmer acquired Oxford Immunotec for $591 million in cash. Under the terms, Oxford Immunotec shareholders will be entitled to receive USD 22.00 in cash for each outstanding ordinary share

Oxford Immunotec is recognized as a global leader of proprietary test kits for latent tuberculosis.